Resources

News

News from Vox.Bio

Everything you need to know about the use of Conjoint in Health Market Research

“Conjoint”, especially in the context of healthcare research, can be considered a daunting and scary...

VoxBio team

Complementary Therapies in Breast Cancer

ASCO has endorsed SIO guidelines to encourage clinicians to discuss alternative therapies with patients Many...

VoxBio team

The Rise of Orals

With four oral JAK-i therapies expected to be available to rheumatoid arthritis patients by the...

VoxBio team

ASCO Highlights

The largest clinical oncology conference provided an insight into the future of oncology care from...

VoxBio team

The Research Ripple Effect

The BHBIA’s Annual Conference did not disappoint again this year. The conference topic ‘The Ripple...

VoxBio team

A Quick Guide to MaxDiff

MaxDiff, also known as best-worst scaling, is a quantitative tool providing prioritisation of needs, attributes...

VoxBio team

UEGW Highlights

Immunology is one of Vox.Bio’s therapeutic areas of expertise and there is a lot happening...

VoxBio team

Market Research with Oncology Patients

Market research with onocology patients, even those with metastatic or terminal diagnosis is not out...

VoxBio team

Why the First 10 Minutes of Qualitative Research are so Important

When budgets are tight and there is a lot of content to cover clients often...

VoxBio team

Digital Health in Respiratory Care

Cambridge’s medical innovation community is exploring how digital technology can help to support and enhance...

VoxBio team

Can Consumer Technology Really Improve Long Term Health Outcomes?

The preliminary results of the Apple Heart Study highlight the potential role that consumer digital...

VoxBio team

Summer Social

For Vox.Bio’s Summer Social event this year we headed out into (a very hot and...

VoxBio team

CAR-T Therapies and the Challenge of Pricing Research

NHS England has become the first EU country to approve a full access deal for...

VoxBio team

How does switching to biosimilars effect patients?

On October 16th AbbVie’s blockbuster Humira will face competition from at least four biosimilars in...

VoxBio team

Happy Holidays!!

Vox.Bio celebrated the holiday season with a lunch in London for our UK based team....

VoxBio team

Empowering patients with pick and mix management tools

Whilst hybrid closed loop systems dominated the sessions and conference narrative at the American Diabetes...

VoxBio team

Is the era of PowerPoint over?

Vox.Bio has just returned from a thought provoking EphMRA conference in Warsaw. A significant number...

VoxBio team

Findacure Rare Disease Showcase

The teams at Vox.Bio and Cambridge Healthcare Research, are really passionate about the therapeutic areas...

VoxBio team

Assessing social data as real-world data: its benefits, its risks, its future

As researchers and practitioners increasingly seek information beyond the traditional boundaries of randomised control trials,...

Private: Sally Waddington

Thin Air, Smart Tech: How MedTech Measures High-Altitude Performance in Mountaineers, Hikers, and Skiers

Five Insights from Wearable Technology about the Impact of High Altitude on the Body Innovation...

Nicole Estermann

Vox.Bio Awarded as Top Consulting Company 2024 by MedTech Outlook

Vox.Bio has been recognised with the award “Top Medical Device Consulting Company in the UK”...

VoxBio team

Vox.Bio Senior Research Executive, Gaia Ferracci PhD, wins EPHMRA’s 2023 Young Professional Grant

We’re thrilled to announce that Gaia Ferracci, Senior Research Executive has been announced as one...

VoxBio team

No more box-ticking: the rise of digitalisation will finally put patients front and centre

Pharmaceutical companies increasingly claim to be ‘patient-centric’ – a ‘tick-box’ buzzword used primarily to improve...

Private: Aneesa Sajid

Looking Back To Look Forward – What can we learn from looking at failed innovation from digital leaders in big tech

We’re passionate about insights and data, and Vox.Bio we believe that looking beyond your own...

Harry Bullimore